Harmonizing Outcomes With Revascularization and Stents in Acute Myocardial Infarction
Status:
Completed
Trial end date:
2010-11-01
Target enrollment:
Participant gender:
Summary
The primary objectives of the trial are:
1. To establish the safety and efficacy of the use of bivalirudin (+ bail-out GP IIb/IIIa
inhibitors) compared to the use of unfractionated heparin + GP IIb/IIIa inhibitors in
patients with acute myocardial infarction undergoing a primary angioplasty strategy.
2. To establish the safety and efficacy of the slow rate release paclitaxel-eluting TAXUS™
stent compared to an otherwise identical uncoated bare metal EXPRESS2™ stent.
Phase:
Phase 3
Details
Lead Sponsor:
Cardiovascular Research Foundation, New York
Collaborators:
Boston Scientific Corporation The Medicines Company